Myocardial Infarction (MI) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Myocardial Infarction Marketed Drugs Overview
Myocardial infarction (MI), colloquially known as “heart attack,” is caused by decreased or complete cessation of blood flow to a portion of the myocardium. In most cases, this occurs as a result of occlusive coronary atherosclerosis superimposed with a luminal thrombus. MI may be “silent,” and go undetected, or it could be a catastrophic event leading to hemodynamic deterioration and sudden death. Most MIs are due to underlying coronary artery disease, the leading cause of death. With coronary artery occlusion, the myocardium is deprived of oxygen.
| Key Mechanisms of Action (Marketed) | Receptor Antagonist, Receptor Agonist, Enzyme Inhibitor, Biological Factor Inhibitor, Ligand Inhibitor, and Enzyme Activator |
| Key Routes of Administration (Marketed) | Oral, Topical, and Injection |
| Key Molecule Types (Marketed) | Small Molecules, Biologic, and Polymer |
The Myocardial Infarction marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Myocardial Infarction (MI). The report also analyzes the clinical and commercial landscapes of Myocardial Infarction, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
| Key Mechanisms of Action | Enzyme Inhibitor, Receptor Antagonist, Biological Factor Inhibitor, Ion Channel Activator, Ligand Inhibitor, Protein and Peptide Inhibitor, and Receptor Agonist |
| Key Routes of Administration | Injection, Topical, Oral, and Inhalational |
| Key Molecule Types | Biologic, Small Molecules, Polymer, and Oligonucleotide |
| Top Sponsors (Marketed and Pipeline Drugs) | Mashhad University of Medical Sciences, Tabriz University of Medical Sciences, General Hospital of the People’s Liberation Army, and AstraZeneca |
Myocardial Infarction (MI) Marketed and Pipeline Drugs – Key Findings
In 2025, GlobalData estimates that the highest diagnosed prevalence of MI cases will be in India and China. India is expected to contribute approximately 37.6% of global cases, followed by China.
Furthermore, Physicians across the 16 major pharmaceutical markets have treatment guidelines to consult for the diagnosis and management of MI patients. The American College of Cardiology (ACC), European Society of Cardiology (ESC), Korean Society of Myocardial Infarction, and Ministry of Health & Family Welfare, Government of India (MoHFW) have the most recently published treatment guidelines.
Myocardial Infarction Marketed Drugs Segmentation by Mechanism of Action
The key mechanisms of action for Myocardial Infarction marketed drugs are receptor antagonist, receptor agonist, enzyme inhibitor, biological factor inhibitor, ligand inhibitor, and enzyme activator among others. Most marketed drugs for MI are receptor antagonists, followed by enzyme inhibitors in 2023.
Myocardial Infarction Marketed Drugs Analysis by MoA, 2023 (%)
For more MoA insights into Myocardial Infarction marketed drugs, download a free report sample
Myocardial Infarction Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for Myocardial Infarction marketed drugs are oral, topical, and injection. In 2023, the most marketed drugs for MI are oral therapies, followed by injectables.
Myocardial Infarction Marketed Drugs Analysis by RoA, 2023 (%)
For more RoA insights into the Myocardial Infarction marketed drugs, download a free report sample
Myocardial Infarction Marketed Drugs Segmentation by Molecule Type
In 2023, most of the marketed drugs for Myocardial Infarction are small molecules. Biologic and polymer are the other significant molecule type in the marketed drugs for Myocardial Infarction.
Myocardial Infarction Marketed Drugs Analysis by Molecule Types, 2023 (%)
For more molecule type insights into the Myocardial Infarction marketed drugs market, download a free report sample
Myocardial Infarction Pipeline Drugs Segmentation by Mechanisms of Action
The key mechanisms of action for Myocardial Infarction pipeline drugs are enzyme inhibitor, receptor antagonist, biological factor inhibitor, ion channel activator, ligand inhibitor, protein and peptide inhibitor, and receptor agonist. In 2023, most of the Myocardial Infarction pipeline drugs are enzyme inhibitor.
Myocardial Infarction Pipeline Drugs Analysis by MoA, 2023 (%)
For more MoA insights into the Myocardial Infarction pipeline drugs market, download a free report sample
Myocardial Infarction Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for Myocardial Infarction pipeline drugs are injection, topical, oral, and inhalational. In 2023, for all the MI pipeline drugs, injectable is the most common route of administration.
Myocardial Infarction Pipeline Drugs Analysis by RoA, 2023 (%)
For more RoA insights into the Myocardial Infarction pipeline drugs market, download a free report sample
Myocardial Infarction Pipeline Drugs Segmentation by Molecule Type
The key molecule types for the Myocardial Infarction drugs market are biologics, small molecules, polymers, and oligonucleotide. In 2023, the MI pipeline is mostly made up of biologics.
Myocardial Infarction Pipeline Drugs Analysis by Molecule Types, 2023 (%)
For more molecule type insights into the Myocardial Infarction pipeline drugs market, download a free report sample
Top Sponsors in the Myocardial Infarction Marketed and Pipeline Drugs Market
Some of the top sponsors in the Myocardial Infarction marketed and pipeline drugs market are Mashhad University of Medical Sciences, Tabriz University of Medical Sciences, General Hospital of the People’s Liberation Army, and AstraZeneca among others. In 2023, Mashhad University of Medical Sciences and Tabriz University of Medical Sciences sponsored the highest number of clinical trials.
Segments Covered in the Report
Myocardial Infarction Marketed Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Agonist
- Receptor Antagonist
- Enzyme Inhibitor
- Biological Factor Inhibitor
- Ligand Inhibitor
- Enzyme Activator
Myocardial Infarction Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Oral
- Topical
- Injection
Myocardial Infarction Marketed Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Small Molecules
- Biologic
- Polymer
Myocardial Infarction Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Enzyme Inhibitor
- Receptor Antagonist
- Biological Factor Inhibitor
- Ion Channel Activator
- Ligand Inhibitor
- Protein and Peptide Inhibitor
- Receptor Agonist
Myocardial Infarction Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Topical
- Oral
- Injection
- Inhalation
Myocardial Infarction Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Small Molecule
- Biologic
- Oligonucleotide
- Polymer
Scope
GlobalData’s Myocardial Infarction (MI) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Myocardial Infarction market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Myocardial Infarction market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which MoA for Myocardial Infarction marketed drugs has the highest share?
Most marketed drugs for MI are receptor antagonists, followed by enzyme inhibitors in 2023.
-
Which RoA for Myocardial Infarction marketed drugs has the highest share?
In 2023, the most marketed drugs for MI are oral therapies, followed by injectables.
-
Which molecule type for Myocardial Infarction marketed drugs has the highest share?
In 2023, most of the marketed drugs for Myocardial Infarction are small molecules.
-
Which MoA for Myocardial Infarction pipeline drugs holds the largest share?
In 2023, most of the Myocardial Infarction pipeline drugs are enzyme inhibitors.
-
Which RoA for Myocardial Infarction pipeline drugs accounts for the highest share?
In 2023, for all the MI pipeline drugs, injectable is the most common route of administration.
-
Which molecule type for Myocardial Infarction pipeline drugs has the highest share?
In 2023, most of the pipeline drugs for MI are biologics.
-
Who are the top sponsors for Myocardial Infarction marketed and pipeline drugs market?
Some of the top sponsors in the Myocardial Infarction marketed and pipeline drugs market are Mashhad University of Medical Sciences, Tabriz University of Medical Sciences, General Hospital of the People’s Liberation Army, and AstraZeneca.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Myocardial Infarction (MI) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Myocardial Infarction reports